December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
76 citations
,
June 2018 in “EMBO Reports” YAP and TAZ proteins are necessary for the development of two types of skin cancer.
19 citations
,
October 1994 in “Tumori Journal” As of 1994, treatments for liver cancer had not significantly improved patient survival.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
February 2026 in “Annals of Case Reports” Tofacitinib helped a patient regrow hair after 40 years of total hair loss.
January 2025 in “Ege Tıp Bilimleri Dergisi” Radiotherapy affects mitochondrial-related genes in metastatic breast cancer cells.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
46 citations
,
January 2007 in “The European Journal of Contraception & Reproductive Health Care” Birth control pills increase the risk of blood clots, especially within the first year and with certain types.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
29 citations
,
June 2014 in “Drug delivery” The new formulation improved the skin absorption of the drug Thiocolchicoside.
January 2024 in “Wiadomości Lekarskie” New markers can detect tumors, aid drug delivery, and treat cancer effectively and safely.
April 2026 in “International Journal of Nanomedicine” Quercetin delivery systems are improving its effectiveness for medical use.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
1 citations
,
January 2009 in “Actas Dermo-Sifiliográficas” Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.
4 citations
,
October 2019 in “Skin Appendage Disorders” Gefitinib can cause hair and eyebrow darkening.
1 citations
,
January 2022 in “Burns” Taurine and apocynin together improve burn healing, especially later in recovery.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
December 2016 in “Indonesian Journal of Tropical and Infectious Disease/Indonesian Journal of Tropical an Infectious Disease” Double pulse dose terbinafine effectively treats kerion type of tinea capitis.
6 citations
,
November 2020 in “JAAD Case Reports” Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
10 citations
,
August 2002 in “British Journal of Ophthalmology” Surgical excision is the best treatment for SCC, but intralesional cidofovir might be a good alternative.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
150 citations
,
June 1999 in “Oncogene”